Inadequate Initial Response is the Top Reason Why Rheumatologists Move Patients from Simponi and Cimzia, According to a New Report from Decision Resources BURLINGTON, Mass., Dec. 7, 2010 /PRNewswire/ ...
EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that there has been a slight increase in ...
The U.S. launch of a biosimilar to AbbVie’s Humira appears to be hurting the copycat’s developer itself. After AbbVie reported a Humira U.S. sales decline of 26% in the first quarter, Amgen said its ...
Every time Charlotte publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
The drug giants moved in near-perfect synchronicity, raising prices for their top-selling arthritis treatments as though they were opposite-corner gas stations bumping up the price of unleaded. The ...
Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative. Alberta, Canada has expanded ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results